Generics of Gilenya Not Likely in US for at Least Another Two Years

Generics of Gilenya Not Likely in US for at Least Another Two Years

315567

Generics of Gilenya Not Likely in US for at Least Another Two Years

A decision by the U.S. Court of Appeals for the Federal Circuit has upheld the validity of a patent for dosing Novartis’ oral multiple sclerosis (MS) treatment Gilenya (fingolimod), the medication’s manufacturer announced. “With this decision, Novartis confirms that it expects no generic versions of Gilenya in the US market for at least the next two years,” the company stated in a press release. The appellate court’s ruling upholds a 2020 decision from the U.S.…

You must be logged in to read/download the full post.